Wedbush Equities Analysts Cut Earnings Estimates for PRAX

Key Points

• Wedbush Equities has reduced their Q3 2025 earnings estimate for Praxis Precision Medicines to ($3.27) per share, down from a previous estimate of ($3.23).
• The consensus rating for Praxis is a "Moderate Buy" with an average price target of $222.36, despite some analysts issuing sell ratings.
• Institutional investors have significantly increased their stakes in Praxis, with some firms reporting increases of over 6,000% in their holdings during the last quarter.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Investment analysts at Wedbush decreased their Q3 2025 earnings per share (EPS) estimates for Praxis Precision Medicines in a report released on Monday, October 20th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($3.27) for the quarter, down from their prior forecast of ($3.23). Wedbush currently has a "Underperform" rating and a $73.00 target price on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. Wedbush also issued estimates for Praxis Precision Medicines' Q4 2025 earnings at ($3.27) EPS, FY2025 earnings at ($13.14) EPS, Q1 2026 earnings at ($3.10) EPS, Q2 2026 earnings at ($3.21) EPS, Q3 2026 earnings at ($3.45) EPS, Q4 2026 earnings at ($3.60) EPS, FY2026 earnings at ($13.36) EPS, FY2027 earnings at ($14.43) EPS, FY2028 earnings at ($10.41) EPS and FY2029 earnings at ($5.15) EPS.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($3.31) EPS for the quarter, topping analysts' consensus estimates of ($3.40) by $0.09.

Several other equities research analysts have also issued reports on the company. Guggenheim set a $350.00 price objective on Praxis Precision Medicines and gave the company a "buy" rating in a research note on Thursday, October 16th. Chardan Capital set a $330.00 price objective on Praxis Precision Medicines and gave the company a "buy" rating in a research note on Friday. Lifesci Capital raised Praxis Precision Medicines to a "strong-buy" rating in a research note on Wednesday, September 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Praxis Precision Medicines in a research note on Wednesday, October 8th. Finally, Needham & Company LLC lifted their price objective on Praxis Precision Medicines from $80.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $222.36.

Praxis Precision Medicines Price Performance

Praxis Precision Medicines stock opened at $190.02 on Wednesday. The firm has a market capitalization of $4.02 billion, a P/E ratio of -15.46 and a beta of 2.62. Praxis Precision Medicines has a one year low of $26.70 and a one year high of $205.89. The business has a fifty day moving average price of $58.24 and a 200-day moving average price of $47.92.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PRAX. Nisa Investment Advisors LLC increased its holdings in shares of Praxis Precision Medicines by 88.3% in the second quarter. Nisa Investment Advisors LLC now owns 629 shares of the company's stock worth $26,000 after buying an additional 295 shares during the period. CWM LLC increased its holdings in shares of Praxis Precision Medicines by 877.9% in the second quarter. CWM LLC now owns 753 shares of the company's stock worth $32,000 after buying an additional 676 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Praxis Precision Medicines by 24.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock worth $77,000 after buying an additional 359 shares during the period. GAMMA Investing LLC increased its holdings in shares of Praxis Precision Medicines by 6,075.4% in the first quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock worth $152,000 after buying an additional 3,949 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Praxis Precision Medicines in the third quarter worth about $207,000. Hedge funds and other institutional investors own 67.84% of the company's stock.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.